Roivant Sciences Ltd (NASDAQ:ROIV) price on current trading day, rose 0.78% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $10.96.
A look at the stock’s price movement, the level at last check in today’s session was $10.87, moving within a range at $10.83 and $11.085. The beta value (5-Year monthly) was 1.243 while the PE ratio in trailing twelve months stood at 1.94. Turning to its 52-week performance, $13.06 and $9.76 were the 52-week high and 52-week low respectively. Overall, ROIV moved -4.90% over the past month.
Roivant Sciences Ltd’s market cap currently stands at around $7.97 billion, with investors looking forward to this quarter’s earnings report slated for in March.
The average forecast suggests down to a -87.21% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 119.45M, representing a -4.28% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ROIV is a 100% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 7 recommend ROIV as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ROIV’s current price about -0.63% and -5.59% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 44.33, while 7-day volatility ratio is 2.27% and 2.65% in the 30-day chart. Further, Roivant Sciences Ltd (ROIV) has a beta value of 1.26, and an average true range (ATR) of 0.30. Analysts have given the company’s stock an average 52-week price target of $17, forecast between a low of $12.5 and high of $17. Looking at the price targets, the low is -14.05% off recent price level in today’s trading while to achieve the yearly target high, it has to move -55.11%. Nonetheless, investors will most likely welcome a -55.11% jump to $17 which is the analysts’ median price.
If we refocus on Roivant Sciences Ltd (NASDAQ:ROIV), historical trading data shows that trading volumes averaged 3.57 over the past 10 days and 4.80 million over the past 3 months. The company’s latest data on shares outstanding shows there are 733.33 million shares.
The 38.43% of Roivant Sciences Ltd’s shares are in the hands of company insiders while institutional holders own 67.72% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 44.88 million on 2025-01-15, giving us a short ratio of 8.38. The data shows that as of 2025-01-15 short interest in Roivant Sciences Ltd (ROIV) stood at 822.0000600000001 of shares outstanding, with shares short rising to 44.2 million registered in 2024-12-13. Current price change has pushed the stock -7.40% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ROIV stock continues to rise going into the next quarter.
